Cannabis Report
Home > Boards > US OTC > Cannabis > OWC Pharmaceutical Research Corp. (OWCP)

PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ --

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (7) | Next 10 | Previous | Next
swamp boy Member Profile
 
Followed By 2
Posts 297
Boards Moderated 0
Alias Born 05/02/17
160x600 placeholder
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/21/2018 9:13:35 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2018 7:30:10 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/17/2018 4:59:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2018 4:10:20 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/14/2018 4:38:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2018 9:16:30 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 7/3/2018 4:41:06 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/3/2018 6:02:25 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 6/28/2018 4:13:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2018 4:07:59 PM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 6/14/2018 5:05:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2018 7:20:39 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2018 5:45:01 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 5/9/2018 4:16:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2018 8:24:29 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2018 12:43:18 PM
Traders News Issues Research on High Growth Canna and Pharma Stocks InvestorsHub NewsWire - 4/25/2018 8:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/16/2018 4:16:50 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/2/2018 6:16:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2018 7:37:23 AM
Vita Mobile (OTC Pink: VMSI) Secures Non-Toxic Equity Funding at a $150 Million Valuation InvestorsHub NewsWire - 3/8/2018 6:50:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2018 6:16:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/20/2018 6:33:51 AM
Traders News Source Focus on Stocks to Watch and a New Cannabis Related Feature Report InvestorsHub NewsWire - 2/13/2018 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 5:02:51 PM
swamp boy   Thursday, 03/08/18 10:37:35 AM
Re: None
Post # of 149107 
PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders.

In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company").

The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.

We have recruited a highly skilled management team with multi-year experience in medical cannabis, pharmaceutical development, corporate management and capital markets.

As we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.

The Company's management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.

As a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our new Chief Scientific Officer and we continue to develop the resources we believe will bolster our endeavors in creating a great company.

Yours sincerely,

Dr. Stanley Hirsch
Chairman of the Board

About


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (7) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist